SFI
ANIP icon

Susquehanna Fundamental Investments’s ANI Pharmaceuticals ANIP Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,440
Closed -$967K – 731
2025
Q1 		$967K Buy
+14,440
New +$862K 0.01% 696
2024
Q2 		$228K Buy
+3,588
New +$233K 0.01% 825
2021
Q1 		– Sell
-12,487
Closed -$363K – 1524
2020
Q4 		$363K Buy
+12,487
New +$358K 0.01% 1210

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Susquehanna Fundamental Investments's ANIP Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of ANI Pharmaceuticals (ANIP) in Q2 2025, closing a stake of 14,440 shares — an estimated $967K sold.

Susquehanna Fundamental Investments first reported a position in ANIP in Q4 2020 and held it in 3 quarters. The position peaked at $967K in Q1 2025. 232 funds tracked by Wall St. Rank hold ANIP as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining ANI Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 14,440 ANI Pharmaceuticals shares in Q2 2025, an estimated $967K.
  • Susquehanna Fundamental Investments first reported a position in ANI Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's ANI Pharmaceuticals position peaked at $967K in Q1 2025.
  • 232 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.